// App-Quantinova.ai

OP0061 : KINERET (ANAKINRA) CONTROLS DISEASE SYMPTOMS IN PATIENTS WITH SEVERE CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES (CAPS): UP TO 5-YEAR FOLLOW-UP DATA

Researchers

Presenter

  • H. Olivecrona

Principal Investigators

  • M. Alden Raboisson

  • K. Soderberg

  • R. Bishop

  • S. Hill

  • S. Paul

  • D. Stone

  • D. Chapelle

  • J. Butman

  • R. Goldbach-Mansky

  • B. Hallen

  • M. Leinonen

  • C. Sibley

  • N. Plass

  • C. Brewer

  • K. King

  • C. Zalewski

  • J. Kim

Medical Centers

  • PledPharma AB, Stockholm, Sweden

  • NIH Clinical Center, Bethesda, MD, United States

Locations

  • United States

  • Sweden

Companies

  • Swedish Orphan Biovi

Study Components

Therapeutic Area

  • Central Nervous System (CNS)

Disease

  • Inflammatory Arthritis

  • Chronic infantile neurologic cutaneous and articular syndrome

  • Familial cold autoinflammatory syndrome 1

  • Cryopyrin associated periodic syndrome

  • Posterior Reversible Encephalopathy Syndrome

Biomarkers

  • High sensitivity C-reactive protein

  • Interleukin 1

  • Serum amyloid A

Drug/Treatment

  • Anakinra

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved